Search

Your search keyword '"Curtin, Peter T."' showing total 48 results
Start Over Author "Curtin, Peter T."
48 results on '"Curtin, Peter T."'

1. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Author

Shah, Neil P., primary, Bhatia, Ravi, additional, Altman, Jessica K., additional, Amaya, Maria, additional, Begna, Kebede H., additional, Berman, Ellin, additional, Chan, Onyee, additional, Clements, Joan, additional, Collins, Robert H., additional, Curtin, Peter T., additional, DeAngelo, Daniel J., additional, Drazer, Michael, additional, Maness, Lori, additional, Metheny, Leland, additional, Mohan, Sanjay, additional, Moore, Joseph O., additional, Oehler, Vivian, additional, Pratz, Keith, additional, Pusic, Iskra, additional, Rose, Michal G., additional, Shomali, William, additional, Smith, B. Douglas, additional, Styler, Michael, additional, Talpaz, Moshe, additional, Tanaka, Tiffany N., additional, Tantravahi, Srinivas, additional, Thompson, James, additional, Tsai, Steven, additional, Vaughn, Jennifer, additional, Welborn, Jeanna, additional, Yang, David T., additional, Sundar, Hema, additional, and Gregory, Kristina, additional

Published
2024
Full Text
View/download PDF

2. Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Author

Othman, Tamer, primary, Aldoss, Ibrahim, additional, Tsai, Ni-Chun, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Ngo, Dat, additional, Chen, Jason, additional, Al Malki, Monzr M., additional, Salhotra, Amandeep, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet S., additional, Arslan, Shukaib, additional, Ball, Brian J, additional, Stewart, Forrest M., additional, Curtin, Peter T., additional, Artz, Andrew S., additional, Snyder, David S, additional, Marcucci, Guido, additional, Forman, Stephen J, additional, Stein, Anthony S., additional, Nakamura, Ryotaro, additional, Pullarkat, Vinod A., additional, Mei, Matthew, additional, and Koller, Paul B., additional

Published
2022
Full Text
View/download PDF

3. Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL

Author

Sandhu, Karamjeet S., primary, Macias, Alan, additional, Del Real, Marissa, additional, Beltran, Asuscena L., additional, Kim, Young Sun, additional, Zhang, Jianying, additional, Palmer, Joycelynne, additional, Robbins, Marjorie, additional, Loomis, Reyna, additional, Akhtari, Mojtaba, additional, Aribi, Ahmed, additional, Arslan, Shukaib, additional, Salhotra, Amandeep, additional, Mei, Matthew, additional, Pourhassan, Hoda, additional, Koller, Paul B., additional, Amanam, Idoroenyi, additional, Agrawal, Vaibhav, additional, Curtin, Peter T., additional, Spielberger, Ricardo, additional, Pullarkat, Vinod A., additional, Aldoss, Ibrahim, additional, Stewart, F. Mark, additional, Smith, Eileen P., additional, Forman, Stephen J, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, and Budde, L. Elizabeth, additional

Published
2022
Full Text
View/download PDF

4. Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors

Author

Koller, Paul B., primary, Shan, Haoyue, additional, Palmer, Joycelynne, additional, Curtin, Peter T., additional, Sandhu, Karamjeet S., additional, Agrawal, Vaibhav, additional, Spielberger, Ricardo, additional, Mansour, Joshua, additional, Blackmon, Amanda, additional, Otoukesh, Salman, additional, Arslan, Shukaib, additional, Amanam, Idoroenyi, additional, Smith, Eileen P., additional, Stewart, Forrest M., additional, Ball, Brian J, additional, Salhotra, Amandeep, additional, Aribi, Ahmed, additional, Aldoss, Ibrahim, additional, Pullarkat, Vinod A., additional, Stein, Anthony S., additional, Artz, Andrew S., additional, Marcucci, Guido, additional, Forman, Stephen J, additional, Nakamura, Ryotaro, additional, Al Malki, Monzr M., additional, Snyder, David S, additional, and Ali, Haris, additional

Published
2022
Full Text
View/download PDF

5. Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation

Author

Markary, Tanya, primary, Nguyen, Tina, additional, Tsai, Ni-Chun, additional, Arslan, Shukaib, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Ball, Brian J, additional, Koller, Paul B., additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Farol, Len, additional, Sandhu, Karamjeet S., additional, Artz, Andrew S., additional, Salhotra, Amandeep, additional, Aldoss, Ibrahim, additional, Pullarkat, Vinod A., additional, Ali, Haris, additional, Curtin, Peter T., additional, Stein, Anthony S., additional, Marcucci, Guido, additional, Forman, Stephen J, additional, Nakamura, Ryotaro, additional, and Al Malki, Monzr M., additional

Published
2022
Full Text
View/download PDF

6. Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Author

Othman, Tamer, primary, Koller, Paul B., additional, Tsai, Ni-Chun, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Ngo, Dat, additional, Chen, Jason, additional, Al Malki, Monzr M., additional, Salhotra, Amandeep, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet S., additional, Arslan, Shukaib, additional, Ball, Brian J, additional, Stewart, Forrest M., additional, Curtin, Peter T., additional, Artz, Andrew S., additional, Snyder, David S, additional, Marcucci, Guido, additional, Forman, Stephen J, additional, Stein, Anthony S., additional, Nakamura, Ryotaro, additional, Pullarkat, Vinod A., additional, Aldoss, Ibrahim, additional, and Mei, Matthew, additional

Published
2022
Full Text
View/download PDF

7. Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation

Author

Agrawal, Vaibhav, primary, Pourhassan, Hoda, additional, Tsai, Ni-Chun, additional, Ngo, Dat, additional, Koller, Paul B., additional, Al Malki, Monzr M., additional, Salhotra, Amandeep, additional, Ali, Haris, additional, Sandhu, Karamjeet S., additional, Arslan, Shukaib, additional, Ball, Brian J, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Artz, Andrew S., additional, Becker, Pamela S., additional, Stewart, Forrest M., additional, Smith, Eileen P., additional, Curtin, Peter T., additional, Stein, Anthony S., additional, Marcucci, Guido, additional, Forman, Stephen J, additional, Nakamura, Ryotaro, additional, Pullarkat, Vinod A., additional, and Aldoss, Ibrahim, additional

Published
2022
Full Text
View/download PDF

8. Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Author

Othman, Tamer, primary, Koller, Paul B., additional, Tsai, Ni-Chun, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Ngo, Dat, additional, Chen, Jason, additional, Al Malki, Monzr M., additional, Salhotra, Amandeep, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet S., additional, Arslan, Shukaib, additional, Ball, Brian J., additional, Stewart, Forrest M., additional, Curtin, Peter T., additional, Artz, Andrew S., additional, Snyder, David S., additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Stein, Anthony S., additional, Nakamura, Ryotaro, additional, Pullarkat, Vinod A., additional, Aldoss, Ibrahim, additional, and Mei, Matthew, additional

Published
2022
Full Text
View/download PDF

9. Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Author

Ali, Haris, primary, Yang, Dongyun, additional, Mokhtari, Sally, additional, Synold, Timothy, additional, Amanam, Idoroenyi, additional, Artz, Andrew S., additional, Curtin, Peter T., additional, Sandhu, Karamjeet S., additional, Stein, Anthony S., additional, Arslan, Shukaib, additional, Otoukesh, Salman, additional, Sahebi, Firoozeh, additional, Mansour, Joshua, additional, Koller, Paul B., additional, Salhotra, Amandeep, additional, Aldoss, Ibrahim, additional, Pullarkat, Vinod A., additional, Ball, Brian J, additional, Forman, Stephen J, additional, Marcucci, Guido, additional, Al Malki, Monzr M., additional, and Nakamura, Ryotaro, additional

Published
2022
Full Text
View/download PDF

10. Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions

Author

Aldoss, Ibrahim, primary, Yang, Dongyun, additional, Afkhami, Michelle, additional, Gu, Zhaohui, additional, Mokhtari, Sally, additional, Shahani, Shilpa, additional, Agrawal, Vaibhav, additional, Pourhassan, Hoda, additional, Koller, Paul B., additional, Tomasian, Vanina, additional, Telatar, Milhan, additional, Al Malki, Monzr M., additional, Salhotra, Amandeep, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet S., additional, Arslan, Shukaib, additional, Ball, Brian J, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Artz, Andrew S., additional, Becker, Pamela S., additional, Stewart, Forrest M., additional, Curtin, Peter T., additional, Pillai, Raju, additional, Smith, Eileen P., additional, Marcucci, Guido, additional, Stein, Anthony S., additional, Forman, Stephen J, additional, Nakamura, Ryotaro, additional, and Pullarkat, Vinod A., additional

Published
2022
Full Text
View/download PDF

12. The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type

Author

Dadwal, Sanjeet S, primary, Yang, Dongyun, additional, Marcucci, Guido, additional, Mokhtari, Sally, additional, Tegtmeier, Bernard, additional, Palmer, Joycelynne, additional, Smith, Eileen P., additional, Taplitz, Randy, additional, Artz, Andrew S., additional, Curtin, Peter T., additional, Spielberger, Ricardo, additional, Salhotra, Amandeep, additional, Stein, Anthony S., additional, Forman, Stephen J, additional, Al Malki, Monzr M., additional, and Nakamura, Ryotaro, additional

Published
2021
Full Text
View/download PDF

13. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL

Author

Aldoss, Ibrahim, primary, Yang, Dongyun, additional, Gu, Zhaohui, additional, Tomazian, Vanina, additional, Mokhtari, Sally, additional, Jackson, Ryan, additional, Telatar, Milhan, additional, Yew, Hooi, additional, Al Malki, Monzr M., additional, Salhotra, Amandeep, additional, Khaled, Samer, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet S., additional, Mei, Matthew, additional, Arslan, Shukaib, additional, Koller, Paul, additional, Artz, Andrew S., additional, Aoun, Patricia, additional, Gu, Dongqing, additional, Snyder, David S, additional, Stewart, F. Mark, additional, Curtin, Peter T., additional, Stein, Anthony S., additional, Pillai, Raju, additional, Marcucci, Guido, additional, Forman, Stephen J, additional, Pullarkat, Vinod A., additional, Nakamura, Ryotaro, additional, and Afkhami, Michelle, additional

Published
2021
Full Text
View/download PDF

18. Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders

Author

Laport, Ginna G., Sandmaier, Brenda M., Storer, Barry E., Scott, Bart L., Stuart, Monic J., Lange, Thoralf, Maris, Michael B., Agura, Edward D., Chauncey, Thomas R., Wong, Ruby M., Forman, Stephen J., Petersen, Finn B., Wade, James C., Epner, Elliot, Bruno, Benedetto, Bethge, Wolfgang A., Curtin, Peter T., Maloney, David G., Blume, Karl G., and Storb, Rainer F.

Published
2008
Full Text
View/download PDF

19. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Author

Raza, Azra, Reeves, James A., Feldman, Eric J., Dewald, Gordon W., Bennett, John M., Deeg, H. Joachim, Dreisbach, Luke, Schiffer, Charles A., Stone, Richard M., Greenberg, Peter L., Curtin, Peter T., Klimek, Virginia M., Shammo, Jamile M., Thomas, Deborah, Knight, Robert D., Schmidt, Michele, Wride, Kenton, Zeldis, Jerome B., and List, Alan F.

Published
2008
Full Text
View/download PDF

21. Dissection of the enhancer activity of beta-globin 5' DNase I-hypersensitive site 2 in transgenic mice

Author

Liu, Depei, Chang, Judy C., Moi, Paolo, We Liu, Kan, Y.W., and Curtin, Peter T.

Subjects
Globin genes -- Expression, Genetically modified mice -- Usage, Science and technology
Abstract

The sequences within the beta-globin 5' DNase I-hypersensitive site 2 (5'HS-2) that are necessary for full enhancer activity in vivo were identified. Several deletion mutants of 5'HS-2 were linked to the human beta-globin gene and their activity was examined in transgenic mice. The results indicate that the nuclear erythroid factor 2/activator protein 1 motif is required for enhancer activity but that other sequences are necessary for full activity.

Published
1992

22. A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Author

Jonas, Brian A., primary, Curtin, Peter T., additional, Schiller, Gary J., additional, Jeyakumar, Deepa, additional, Wieduwilt, Matthew J., additional, Abedi, Mehrdad, additional, Bejar, Rafael, additional, Chow, Helen, additional, Oesterich, Leslie G., additional, and Logan, Aaron C., additional

Published
2018
Full Text
View/download PDF

23. A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

Author

Wieduwilt, Matthew J., primary, Jonas, Brian A., additional, Schiller, Gary J., additional, Liu, Lin, additional, Mulroney, Carolyn, additional, Mannis, Gabriel N., additional, Tzachanis, Dimitrios, additional, Castro, Januario E., additional, Ball, Edward D, additional, Curtin, Peter T., additional, Andreadis, Charalambos, additional, Logan, Aaron C., additional, Reiner, Jesika, additional, and Damon, Lloyd E., additional

Published
2018
Full Text
View/download PDF

28. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Author

DeAngelo, Daniel J., primary, Stone, Richard M., additional, Heaney, Mark L., additional, Nimer, Stephen D., additional, Paquette, Ronald L., additional, Klisovic, Rebecca B., additional, Caligiuri, Michael A., additional, Cooper, Michael R., additional, Lecerf, Jean-Michel, additional, Karol, Michael D., additional, Sheng, Shihong, additional, Holford, Nick, additional, Curtin, Peter T., additional, Druker, Brian J., additional, and Heinrich, Michael C., additional

Published
2006
Full Text
View/download PDF

29. Prognostic Models for Predicting Outcomes after Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin’s Disease: How Predictive Are They?.

Author

Leis, Jose F., primary, Hansen, Keith S., additional, Curtin, Peter T., additional, Hayes-Lattin, Brandon M., additional, Lanier, Keith S., additional, Stanton, Nathan R., additional, Callaway, Charles D., additional, Fowler, Ceder J., additional, Dunn, Adam M., additional, Gruenberg, Daniel, additional, Mauro, Michael J., additional, Segal, Gerald M., additional, Hansen, Lisa K., additional, Menashe, Jeffrey I., additional, Kovacsovics, Tibor J., additional, Simic, Aleksandra, additional, and Maziarz, Richard T., additional

Published
2005
Full Text
View/download PDF

30. Survival after Autologous Transplantation to Treat Diffuse Large B-Cell Lymphoma with a History of CNS Involvement, Bone Marrow Involvement, or Histologic Transformation.

Author

Hayes-Lattin, Brandon, primary, Mehta, Pritesh, additional, Dunn, Adam, additional, Subbiah, Nan, additional, Leis, Jose F., additional, Simic, Aleksandra, additional, Allen, Bryon, additional, Balliesen, Suzanne, additional, Curtin, Peter T., additional, Epner, Elliot, additional, Fleming, William H., additional, Jacoby, Carol, additional, Mauro, Michael J., additional, Nichols, Craig R., additional, Schubach, Susan, additional, and Maziarz, Richard T., additional

Published
2004
Full Text
View/download PDF

31. Safety and Tolerability of Anti-Bacterial Prophylaxis during the Post-Engraftment Phase after Myeloablative Hematopoietic Stem Cell Transplantation.

Author

Hayes-Lattin, Brandon, primary, Bubalo, Joseph, additional, Dunn, Adam, additional, Subbiah, Nan, additional, Allen, Bryon, additional, Balleisen, Suzanne, additional, Curtin, Peter T., additional, Jacoby, Carol, additional, Leis, Jose F., additional, Mauro, Michael J., additional, Simic, Aleksandra, additional, Schubach, Susan, additional, and Maziarz, Richard T., additional

Published
2004
Full Text
View/download PDF

36. Blood: Textbook of Hematology

Author

Shuman, Marc A., Cohen, Robert L., and Curtin, Peter T.

Subjects
Blood: Textbook of Hematology (Book) -- Book reviews, Books -- Book reviews
Published
1992

37. Hematology: Basic Principles and Practice

Author

Shuman, Marc A., Cohen, Robert L., and Curtin, Peter T.

Subjects
Hematology: Basic Principles and Practice (Book) -- Book reviews, Books -- Book reviews
Published
1992

38. Hematology, 4th ed

Author

Shuman, Marc A., Cohen, Robert L., and Curtin, Peter T.

Subjects
Hematology, 4th Ed (Book) -- Book reviews, Books -- Book reviews
Published
1992

40. Introduction to Hematology, 2d ed

Author

Shuman, Marc A., Cohen, Robert L., and Curtin, Peter T.

Subjects
Introduction to Hematology, 2d Ed (Book) -- Book reviews, Books -- Book reviews
Published
1992

41. Hematology, 5th ed

Author

Shuman, Marc A., Cohen, Robert L., and Curtin, Peter T.

Subjects
Hematology, 5th Ed (Book) -- Book reviews, Books -- Book reviews
Published
1992

42. Blood: Pathophysiology

Author

Shuman, Marc A., Cohen, Robert L., and Curtin, Peter T.

Subjects
Blood: Pathophysiology (Book) -- Book reviews, Books -- Book reviews
Published
1992

44. The Inactive β Globin Gene on a γδβThalassemia Chromosome Has a Normal Structure and Functions Normally in vitro

Author

Curtin, Peter T. and Kan, Yuet Wai

Abstract

We have previously described an English family with γδβ -thalassemia in which a large deletion stops 25 kilobases (kb) upstream from the β-globin gene locus, and yet the β-globin gene is inactive in vivo. Affected family members had a β-thalassemia minor phenotype with a normal hemoglobin A2level. Gene mapping showed that these subjects were heterozygous for a chromosome bearing a large deletion that began in the °γ-globin gene, extended through the €-globin gene, and continued upstream for at least 75 kb. The Aγ-,δ-, and β-globin gene loci on this chromosome were intact. To examine the possibility that an additional defect was present in the β-globin gene, we cloned, sequenced, and examined the expression of the β-globin gene from the affected chromosome. No mutation was found in the β -globin gene sequence from 990 base-pairs 5’ to the cap site to 350 basepairs 3’ to the polyade-nylation signal. The gene was subcloned into an expression vector and introduced into HeLa cells. Analysis of RNA derived from these cells, using a ribonuclease protection assay, revealed qualitatively and quantitatively normal transcription. Thus a structurally and functionally normal β -globin gene is inactive in the presence of a large deletion more than 25 kb upstream. The loss of β -globin gene function may be due to disturbance of chromatin conformation caused by the deletion or may be the result of loss of upstream sequences that are necessary for β -globin gene expression in vivo.

Published
1988
Full Text
View/download PDF

46. A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Author

Jonas, Brian A, Logan, Aaron C., Jeyakumar, Deepa, Abedi, Mehrdad, Bejar, Rafael, Wieduwilt, Matthew J., Oesterich, Leslie G., and Curtin, Peter T.

Abstract

Introduction: Higher risk myelodysplastic syndromes (HR-MDS) have poor outcomes, particularly after hypomethylating agent (HMA) failure. The HMA azacitidine (AZA) is a standard of care for HR-MDS and works through several mechanisms, including inhibition of NF-kB signaling. Ibrutinib (IBR) inhibits Bruton's Tyrosine Kinase (BTK) and has an antiproliferative effect on myeloblasts in preclinical models through BTK binding and inhibition of NF-kB signaling. IBR also has immunomodulatory activity mediated through binding interleukin-2-inducible kinase (ITK) and promoting Th1-polarized immunity, which is decreased in HR-MDS. These features suggest that the combination of IBR and AZA may improve outcomes in HR-MDS.

Published
2017
Full Text
View/download PDF

47. Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin-2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease.

Author

Emery, Sean, Capra, William B., Cooper, David A., Mitsuyasu, Ronald T., Kovacs, Joseph A., Vig, Pamela, Smolskis, Mary, Saravolatz, Louis D., Lane, H. Clifford, Fyfe, Gwen A., and Curtin, Peter T.

Subjects
HIV, INTERLEUKINS
Abstract

Focuses on the survival of human immunodeficiency virus (HIV) disease progression. Basis on the statistical analysis of HIV disease progression; Examination of interleukin as a potent simulator of T cell proliferation and maturation; Success on combining antiretroval therapy and antimicrobial prophylaxis in treating HIV-infection.

Published
2000
Full Text
View/download PDF

48. Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.

Author

Leis JF, Primack SL, Schubach SE, Curtin PT, Druker BJ, and Maziarz RT

Subjects
Aged, Apoptosis drug effects, Benzamides, Dyspnea etiology, Humans, Imatinib Mesylate, Leukostasis diagnostic imaging, Leukostasis etiology, Lung diagnostic imaging, Male, Remission Induction, Tomography, X-Ray Computed, Antineoplastic Agents therapeutic use, Blast Crisis complications, Leukemia, Myelogenous, Chronic, BCR-ABL Positive complications, Leukostasis drug therapy, Lung blood supply, Piperazines therapeutic use, Pyrimidines therapeutic use
Abstract

Pulmonary leukostasis is a rare but serious and often fatal complication of chronic myeloid leukemia (CML) in blast crisis and acute myeloid leukemia. Treatment options are limited for these patients. Imatinib mesylate (STI-571, Gleevec, Novartis) is a potent and selective inhibitor of the BCR-abl tyrosine kinase, the molecular abnormality that causes CML. The case of a 74-year-old man with a history of CML who presented in myeloid blast crisis with pulmonary leukostasis characterized by increasing dyspnea, hypoxemia, fever, and impending respiratory failure is reported. The patient was treated with single agent imatinib mesylate (IM) with rapid decrease in his white blood cell count (WBC) and marked improvement in his respiratory status. No electrolyte abnormalities consistent with tumor lysis syndrome were observed. IM may be an effective single agent therapy for pulmonary leukostasis in patients with CML blast crisis who are at the risk for tumor lysis.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results